Peptide Schedule
Gotratix5 residuesAEDRGEach bubble = one amino acid. Size = residue mass. Color = chemical class.Gotratix Dosage Calculator
Gotratix is a muscle-targeted peptide bioregulator in the Khavinson class, extracted from the striated muscle tissue of young calves through acid hydrolysis and ultrafiltration.
200mcg · Daily
Summary: Add 0mL BAC water to your 200mg vial. Draw to < 0.1 units on a U-100 syringe for a 200mcg dose. This vial will last 0 doses.
Cycle Planner
Gotratix Pharmacokinetics
Pharmacokinetics — Active Dose Over Time
t½ = ~2-4 hours (estimated, short peptide complex)Disclaimer: This curve is a simplified first-order exponential decay model. Actual pharmacokinetics vary based on injection site, individual metabolism, body composition, and other factors. Half-life values are approximate and based on available preclinical and clinical literature. Many research peptides lack formal human pharmacokinetic studies. This is for educational purposes only — not medical advice.
Gotratix Dosing Protocol
| Level | Dose / Injection | Frequency |
|---|---|---|
| Beginner | 200mg | Daily |
| Moderate | 400mg | 2x Daily |
| Aggressive | 400mg | 3x Daily |
Note: Gotratix (A-18) is a Khavinson-class peptide bioregulator derived from the triceps muscle tissue of young calves. It's supplied as oral capsules containing 200 mg of peptide complex per capsule. Standard courses run 1-2 months, repeated every 4-6 months. As a polypeptide complex rather than a single defined peptide, detailed pharmacokinetic data for individual components hasn't been published. No clinical trials have been registered on ClinicalTrials.gov, and the evidence base is limited to Khavinson's broader bioregulator research platform rather than Gotratix-specific studies.
About Gotratix
Gotratix is a muscle-targeted peptide bioregulator in the Khavinson class, extracted from the striated muscle tissue of young calves through acid hydrolysis and ultrafiltration. Developed at the St. Petersburg Institute of Bioregulation and Gerontology, it contains a standardized mix of short-chain peptides (2-7 amino acid residues) with molecular weights below 10 kDa that are thought to selectively interact with myocyte gene promoter regions. The product is available in 200 mg oral capsules and doesn't require injection or reconstitution. According to the bioregulator model proposed by Vladimir Khavinson, these tissue-derived peptides can cross cell membranes and enter the nucleus, where they bind to specific DNA sequences in gene promoter regions. For muscle tissue, this is claimed to normalize protein synthesis within myocytes, restore cellular metabolism, and increase functional reserve capacity. Gotratix is marketed primarily for supporting muscle recovery, reducing fatigue during intense physical activity, and maintaining muscle function during aging. While the broader Khavinson bioregulator research program spans over 40 years and includes published studies on compounds like Cortexin and Epithalon, Gotratix itself lacks dedicated clinical trials in peer-reviewed international journals. The evidence supporting its muscle-specific claims comes mainly from the general bioregulator framework — the idea that organ-specific peptide extracts restore function in their tissue of origin — rather than controlled human studies of this particular product. Users should treat manufacturer claims with caution and understand that the regulatory status remains research-only outside of Russia and CIS countries.